Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.

A letter to the editor is presented which discusses a study on the impact of additional cytogenetic abnormalities (ACA) on the response and survival of patients with late chronic phase chronic myeloid leukemia (CML), who were treated with the Bcr-Abl tyrosine kinase imatinib mesylate.